Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy

NCT01006122 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01006122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01006122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 2, Double Blind, Placebo-Controlled, Multi-Center Crossover Study Of PF-03654746 As A Daily Treatment For Excessive Daytime Sleepiness (EDS) Associated With Narcolepsy
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2009
Completion date
November 30, 2010
Enrollment
95 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

excessive daytime sleepiness, narcolepsy